Gravipiride M 3 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and increases peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The synergistic action of these two agents offers effective glycemic regulation in patients inadequately controlled by diet, exercise, or monotherapy. Gravipiride M 3 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rare cases of lactic acidosis. Regular monitoring of blood glucose levels, renal function, and periodic assessment of glycemic control is recommended to optimize therapy and minimize risks. Patients should be advised to adhere strictly to prescribed dosages and report any adverse symptoms promptly to their healthcare provider.